Abstract：
OBJECTIVE: Musculoskeletal pain may occur after becoming infected with SARS-Cov2. This study was designed to evaluate the efficacy of mesotherapy in treating chronic pain following COVID-19 infection.
METHODS: A retrospective review was conducted of the records of 96 patients with post-COVID pain syndrome. Those who were eligible for oral therapy or mesotherapy, included in the study. Patients receiving oral treatment with diclofenac potassium, thiocolchicoside and cyanocobalamin were included in one group (n = 46), and patients receiving intradermal mesotherapy with 2% lidocaine + cyanocobalamin were included in another group (n = 50). The results of the Visual Analogue Scale (VAS) and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) were individually assessed before and one week after the treatment.
RESULTS: The participants were 40.2 ± 11.1 years old on average. Of the participants, 35.4% (n = 34) were male and 64.6% (n = 62) were female. Before treatment, there was no statistically significant difference between the patients in terms of VAS and LANSS scores. Following the treatment, a notable positive response was observed in both groups. Nevertheless, when compared to the oral treatment group, the mesotherapy group exhibited a more pronounced enhancement in VAS and LANSS scores (P < 0.001, P < 0.001, respectively).
CONCLUSIONS: While both mesotherapy and oral therapy offer benefits in reducing pain and alleviating neuropathic symptoms in post-COVID pain syndrome, mesotherapy stands out as an especially effective and well-tolerated treatment method, surpassing the efficacy of the oral alternative.
METHODS: A retrospective review was conducted of the records of 96 patients with post-COVID pain syndrome. Those who were eligible for oral therapy or mesotherapy, included in the study. Patients receiving oral treatment with diclofenac potassium, thiocolchicoside and cyanocobalamin were included in one group (n = 46), and patients receiving intradermal mesotherapy with 2% lidocaine + cyanocobalamin were included in another group (n = 50). The results of the Visual Analogue Scale (VAS) and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) were individually assessed before and one week after the treatment.
RESULTS: The participants were 40.2 ± 11.1 years old on average. Of the participants, 35.4% (n = 34) were male and 64.6% (n = 62) were female. Before treatment, there was no statistically significant difference between the patients in terms of VAS and LANSS scores. Following the treatment, a notable positive response was observed in both groups. Nevertheless, when compared to the oral treatment group, the mesotherapy group exhibited a more pronounced enhancement in VAS and LANSS scores (P < 0.001, P < 0.001, respectively).
CONCLUSIONS: While both mesotherapy and oral therapy offer benefits in reducing pain and alleviating neuropathic symptoms in post-COVID pain syndrome, mesotherapy stands out as an especially effective and well-tolerated treatment method, surpassing the efficacy of the oral alternative.
摘要：
目的：感染SARS-Cov2后可能会发生肌肉骨骼疼痛。本研究旨在评估中胚层疗法治疗COVID-19感染后慢性疼痛的疗效。
方法：对96例COVID后疼痛综合征患者的记录进行回顾性分析。那些有资格接受口服治疗或中胚层治疗的人，包括在研究中。接受双氯芬酸钾口服治疗的患者，硫代秋葵苷和氰钴胺被包括在一组（n=46），接受2%利多卡因+氰钴胺皮内治疗的患者被纳入另一组(n=50).在治疗前和治疗后一周分别评估视觉模拟评分（VAS）和利兹神经病变症状和体征评估（LANSS）的结果。
结果：参与者平均年龄为40.2±11.1岁。在参与者中，男性占35.4%(n=34)，女性占64.6%(n=62)。治疗前,两组患者的VAS和LANSS评分无统计学差异.治疗后,两组均观察到显著的阳性反应.然而，与口服治疗组相比，美体疗法组的VAS和LANSS评分提高更明显(分别为P<0.001,P<0.001).
结论：虽然美塑疗法和口服疗法在减轻COVID后疼痛综合征的疼痛和缓解神经性症状方面都有益处，美速疗法是一种特别有效且耐受性良好的治疗方法，超过口服替代的功效。
方法：对96例COVID后疼痛综合征患者的记录进行回顾性分析。那些有资格接受口服治疗或中胚层治疗的人，包括在研究中。接受双氯芬酸钾口服治疗的患者，硫代秋葵苷和氰钴胺被包括在一组（n=46），接受2%利多卡因+氰钴胺皮内治疗的患者被纳入另一组(n=50).在治疗前和治疗后一周分别评估视觉模拟评分（VAS）和利兹神经病变症状和体征评估（LANSS）的结果。
结果：参与者平均年龄为40.2±11.1岁。在参与者中，男性占35.4%(n=34)，女性占64.6%(n=62)。治疗前,两组患者的VAS和LANSS评分无统计学差异.治疗后,两组均观察到显著的阳性反应.然而，与口服治疗组相比，美体疗法组的VAS和LANSS评分提高更明显(分别为P<0.001,P<0.001).
结论：虽然美塑疗法和口服疗法在减轻COVID后疼痛综合征的疼痛和缓解神经性症状方面都有益处，美速疗法是一种特别有效且耐受性良好的治疗方法，超过口服替代的功效。
